Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing.
Takashi NodaNobuhiko UedaYuji TanakaYoko IshiguroTomoko MatsumotoTatsuhiro UenishiHiroko YamaguchiAyako ShojiJae-Eun MyungKengo F KusanoPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)
According to a willingness to pay threshold of 5 million JPY/QALY, the devices with rATP were cost-effective compared with control devices without rATP, showing that the higher reimbursement price of the functional categories with rATP is justified from a healthcare economic perspective.